Poor
Major Misalignment
Patient Risk:
High
Summary
Many claims are not supported by the provided label excerpts, including antihistamine-specific interaction/effectiveness and statements about other statins (rosuvastatin, simvastatin, pravastatin, fluvastatin, pitavastatin). Atorvastatin-specific safety statements are partly supported, but one claim includes pancreatitis and another mischaracterizes serious/rare events as “common side effects.”
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin that reduces production of low-density lipoprotein (LDL) cholesterol in the liver.
12.1 Mechanism of Action (inhibits HMG-CoA reductase/cholesterol synthesis in the liver; reduces LDL production and increases hepatic LDL receptor uptake/catabolism).
Common side effects of Lipitor include muscle damage, kidney problems, and liver damage.
5.1 Skeletal Muscle (rare rhabdomyolysis with acute renal failure secondary to myoglobinuria; myopathy) and 5.2 Liver Dysfunction / 6 ADVERSE REACTIONS (liver enzyme abnormalities; rhabdomyolysis/myopathy discussed).
In rare cases, Lipitor may cause serious side effects such as rhabdomyolysis and pancreatitis.
5.1 Skeletal Muscle (rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria).
Unsupported Statements
The combination of Lipitor with antihistamines can lead to adverse interactions.
No antihistamine-specific interaction is supported by the provided label excerpts (only specific interacting agents/drug classes are discussed for myopathy risk).
Diphenhydramine (Benadryl) can increase the risk of muscle damage and kidney problems when taken with Lipitor.
No diphenhydramine-specific interaction statement is present in the provided excerpts.
Fexofenadine (Allegra) may interact with Lipitor and reduce its effectiveness.
No fexofenadine-specific interaction or effectiveness reduction statement is present in the provided excerpts.
Crestor (rosuvastatin) is effective in reducing LDL cholesterol levels.
No rosuvastatin labeling content is provided in the excerpts.
Crestor (rosuvastatin) has been found to be safe and well-tolerated in patients taking antihistamines.
No rosuvastatin or antihistamine coadministration safety/tolerability information is provided.
Zocor (simvastatin) is a statin used to manage high cholesterol levels.
No simvastatin labeling content is provided in the excerpts.
Zocor (simvastatin) may interact with certain antihistamines such as diphenhydramine.
No simvastatin or diphenhydramine interaction information is provided in the excerpts.
Zocor (simvastatin) is generally considered safe to take with other types of antihistamines.
No simvastatin or antihistamine coadministration safety statement is provided in the excerpts.
Pravachol (pravastatin) is effective in reducing LDL cholesterol levels.
No pravastatin labeling content is provided in the excerpts.
Pravachol (pravastatin) minimizes the risk of muscle damage and kidney problems.
No pravastatin-specific risk minimization language is provided in the excerpts.
Pravachol (pravastatin) has been found to be safe and well-tolerated in patients taking antihistamines.
No pravastatin or antihistamine coadministration safety/tolerability information is provided in the excerpts.
Lescol (fluvastatin) is used to treat high cholesterol levels.
No fluvastatin labeling content is provided in the excerpts.
Lescol (fluvastatin) reduces the risk of cardiovascular disease.
No fluvastatin labeling content (including cardiovascular risk reduction) is provided in the excerpts.
Lescol (fluvastatin) may interact with certain antihistamines such as fexofenadine.
No fluvastatin/fexofenadine interaction information is provided in the excerpts.
Lescol (fluvastatin) is generally considered safe to take with other types of antihistamines.
No fluvastatin or antihistamine coadministration safety statement is provided in the excerpts.
Livalo (pitavastatin) is effective in reducing LDL cholesterol levels.
No pitavastatin labeling content is provided in the excerpts.
Livalo (pitavastatin) minimizes the risk of muscle damage and kidney problems.
No pitavastatin-specific risk minimization language is provided in the excerpts.
Livalo (pitavastatin) has been found to be safe and well-tolerated in patients taking antihistamines.
No pitavastatin or antihistamine coadministration safety/tolerability information is provided in the excerpts.
Some statins may be more effective in reducing LDL cholesterol levels.
No comparative statin effectiveness information is provided in the excerpts.
Switching to a different statin may help minimize the risk of adverse reactions and interactions with other medications.
No label guidance provided in the excerpts about switching statins to mitigate adverse reactions/interactions.
Contradictions
Low
AI Statement
Common side effects of Lipitor include muscle damage, kidney problems, and liver damage.
Label Reference
5.1 Skeletal Muscle and 5.2 Liver Dysfunction describe serious abnormalities/rare rhabdomyolysis/myopathy and liver enzyme abnormalities; the claim characterizes these as “common side effects,” which is not supported by the provided excerpts.
Important Omissions
Atorvastatin-specific interaction guidance should be limited to label-supported interacting agents/classes (e.g., strong CYP3A4 inhibitors, cyclosporine, fibric acid derivatives, niacin, etc.) rather than unspecified “antihistamines.”
Importance:
High
If discussing serious adverse reactions, pancreatitis risk is not supported by the provided excerpts for Lipitor; it should not be included unless supported elsewhere in the full label.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Several claims about antihistamine-specific interactions/effectiveness and multiple non-atorvastatin statins are not supported by the provided label excerpts. Additionally, pancreatitis is included despite not being supported in the provided atorvastatin sections, and serious/rare events are described as “common side effects,” potentially misleading risk perception.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Major Misalignment
Primary Issue
Unsubstantiated antihistamine-specific interaction/effectiveness claims and unsupported statements about other statins not covered by the provided label excerpts; pancreatitis claim not supported; “common side effects” framing not supported.
Suggested Improvement
Restrict claims to the provided atorvastatin (Lipitor) label content, remove antihistamine-specific interaction/effectiveness assertions unless supported, avoid discussing other statins (Crestor/Zocor/Pravachol/Lescol/Livalo) without corresponding label evidence, and do not add pancreatitis as an atorvastatin serious adverse reaction unless supported by the provided label.